Identification of therapies targeting lipid metabolism & myelination for Charcot-Marie-Tooth disease type 1A using patient derived Schwann cells
Identification of therapies targeting lipid metabolism & myelination for Charcot-Marie-Tooth disease type 1A using patient derived Schwann cells (CMT-LIPID)
Ontrafelen van een nieuw pathomechanisme van de ziekte van Charcot-Marie-Tooth en de therapeutische toepasbaarheid.
Ontrafelen van de moleculaire basis en genetische epidemiologie van Charcot-Marie-Tooth neuropathieën: bijdrage van Noordoost-Brazilië.
Ontrafelen van de moleculaire architectuur van autosomaal recessieve Charcot-Marie-Tooth neuropathieën.
Dominant NARS1 mutations causing axonal Charcot–Marie–Tooth disease expand NARS1 -associated diseases
Animal models of Charcot-Marie-Tooth disease and their relevance for understanding the disease in humans
Fast responses to stepping on an unexpected surface height depend on intact large-diameter nerve fibers: a study on Charcot-Marie-Tooth type 1A disease